James Hardiman promoted to General Partner at DCVC - July 2023 NOETIK partners with GSK in landmark AI drug licensing deal - Jan 2026 Valar Labs AI biomarker changes pancreatic cancer treatment paradigm - Feb 2026 Alta Resource Technologies raises $10M seed round for protein-based critical minerals - May 2025 Remedy robot completes world's first remote neurointervention - Oct 2025 DCVC fund total: $2B+ deployed across deep tech - Ongoing James Hardiman: physicist at heart, GP in practice James Hardiman promoted to General Partner at DCVC - July 2023 NOETIK partners with GSK in landmark AI drug licensing deal - Jan 2026 Valar Labs AI biomarker changes pancreatic cancer treatment paradigm - Feb 2026 Alta Resource Technologies raises $10M seed round for protein-based critical minerals - May 2025 Remedy robot completes world's first remote neurointervention - Oct 2025 DCVC fund total: $2B+ deployed across deep tech - Ongoing James Hardiman: physicist at heart, GP in practice

Deep Tech Investor • General Partner • DCVC

James
Hardiman

General Partner — DCVC • San Francisco

A physicist who spent years on semiconductor fab floors before ever writing a check. Now he backs the science most investors can't read - and the companies most capital avoids until it's obvious.

Deep Tech VC AI + Biotech Quantum Robotics Climate Seed to Series B
James Hardiman, General Partner at DCVC James Hardiman • DCVC
2013 At DCVC Since
$725M Latest Fund
20+ Board Seats
~$15M Check Sweet Spot
$2B+ Total DCVC Raised
45 DCVC Team Size

The Physicist
Running the Fund

There are venture capitalists who talk about deep tech. Then there are people who spent years inside a cleanroom at Lam Research, troubleshooting the semiconductor processes that make modern chips possible. James Hardiman did the second thing first.

Today, Hardiman is a General Partner at DCVC - Data Collective Venture Capital - a Palo Alto-based firm that has quietly built one of the most technically sophisticated portfolios in venture capital. He joined in 2013, when the firm was still cutting its teeth on its first institutional fund. He was made General Partner in July 2023.

The future is going to be awesome - all that's required is that we all work hard together to make it happen.

- James Hardiman, on X/Twitter

His investment focus lives at a specific intersection: technologies that can be deployed at scale because they're grounded in real physics, real biology, real chemistry. Not software imitating hard science - the actual hard science, translated into deployable products. That means AI platforms applied to biology and manufacturing, tools that measure and manipulate biological systems, industrial robotics, novel materials, and frontier compute like quantum.

His portfolio reads like a syllabus for the next decade of industry. Lumafield reimagines industrial X-ray scanning with CT technology once reserved for medical labs. Q-CTRL makes quantum computers reliable enough to use through error suppression software. NOETIK is building AI-native biotech - cancer therapeutics where the intelligence is baked into the molecule design. Valar Labs is using AI-derived biomarkers to change how pancreatic cancer is treated.

In early 2025, Hardiman led DCVC's investment in Alta Resource Technologies - a company using computationally optimized proteins to produce critical minerals. It's the kind of deal that sounds like science fiction and reads like a geopolitical hedge.

His investment range runs $5M to $25M, with a sweet spot around $15M. He takes board seats, not just logos. He writes about what he's backing, which means his published work on the DCVC blog functions as a running thesis - each piece a dispatch from whichever frontier he's currently watching most closely.

A Decade-Long
Bet on Hard Science

2005 - 2007 Technical Intern, Lam Research - Working inside semiconductor processing equipment, one of the world's most precision-demanding environments.
2007 - 2012 Consultant, ZS Associates - Data-driven sales and marketing strategy for large life-science and healthcare companies. Learning to speak both scientific and commercial.
2012 - 2014 MBA, University of Chicago Booth - Including a Summer Associate role at The Blackstone Group, M&A advisory track.
2013 Joins DCVC - Shortly after the firm raises its first institutional fund. Deep tech VC was not yet fashionable.
2018 Creative Destruction Lab Mentor - Advising early-stage deep tech founders in AI and Neuro streams at CDL-Toronto.
2020 Board Director at Lumafield - The industrial CT scanning startup that brings medical-grade imaging to manufacturing quality control.
2021 Board Observer at Amogy - Ammonia-to-power clean energy company targeting the hardest-to-decarbonize sectors.
2023 Promoted to General Partner - One of four partners elevated at DCVC, alongside Alan Cohen, Jason Pontin, and Ali Tamaseb.
2025 - 2026 Active Deployment - Led Alta Resource Technologies seed round; published analyses on Valar Labs and NOETIK milestones.

GP at DCVC; physicist at heart; interested in hard tech solving real problems.

- James Hardiman, Twitter bio

Hardiman's path to venture capital is unusual in the best way. He arrived with hands already dirty from real science - semiconductor processing at Lam Research, then years of sitting across from life sciences executives at ZS Associates, learning to translate data into decisions that matter at scale.

The Blackstone summer is the final layer: financial deal structure layered over technical and commercial fluency. That combination - physicist, consultant, banker, then investor - means he reads a technical data room the way most partners read a pitch deck.

Where Hard Science
Meets Large Markets

Hardiman's investments share one quality: they're grounded in physics, biology, or chemistry that doesn't have shortcuts. He's not hunting for clever apps. He's looking for science that reshapes entire industries when it works.

🧬 Biological Systems Characterize. Model. Manipulate.
🤖 Robotics & Automation Real-world industrial deployment
⚛️ Quantum Computing Error suppression + applications
🧪 AI + Chemistry Materials design & synthesis
🏭 Industrial AI Vertical-specific applications
🌱 Climate & Resources Critical minerals + clean energy

The Companies
Reshaping Industry

Hardiman's board seats tell the story better than any thesis statement. Across 20+ companies, the through-line is science that's genuinely difficult to do, deployed into industries large enough to matter. The deals range from $5M to $25M, with active board engagement - not passive logos on a portfolio page.

Lumafield 3D Industrial Imaging Board Director since 2020
Q-CTRL Quantum Error Suppression Portfolio Company
NOETIK AI-Native Biotech / Oncology Portfolio Company
Valar Labs AI Biomarkers / Cancer Portfolio Company
Slip Robotics Warehouse Robotics Portfolio Company
Alta Resource Tech. Protein-Based Critical Minerals Led $10M Seed (2025)
Amogy Ammonia Clean Energy Board Observer since 2021
Recursion Pharmaceuticals Computational Drug Discovery Portfolio Company
Shennon Biotechnologies Biotech Portfolio Company
nTopology Generative Design Software Portfolio Company
Gro Intelligence Agricultural Data Services Portfolio Company
Remedy Robotics Surgical Robotics / Neuro Portfolio Company

Writing from
the Frontier

Hardiman publishes on the DCVC blog whenever something in his portfolio crosses a threshold worth marking. The pieces aren't press releases. They're working documents - evidence of how he thinks, what he cares about, and where the field is going from his vantage point.

Recent examples cover Valar Labs' breakthrough on AI-derived biomarkers for pancreatic cancer treatment; NOETIK's partnership with pharmaceutical giant GSK, which he frames as validation of AI drug licensing as a standalone business model; and Remedy Robotics' achievement of the world's first remote neurointervention procedure.

The through-line in all of it: science that looks impossible until it demonstrably isn't.

The Physicist's
Edge

At DCVC, the brand promise is that the partners can actually read what the founders are building. Hardiman fits that spec unusually well. He didn't come to tech from finance - he arrived from the other direction. Physics first, then strategy consulting for healthcare and biotech, then an MBA with a Blackstone summer, then investing.

That sequencing gives him something rare: he knows what's actually hard versus what just sounds hard. Semiconductor processing at Lam Research is not the same kind of difficult as writing a pitch deck about semiconductor processing. He's done the first thing, which means founders can't bluff him on the second.

His focus on "technologies that characterize, model, or manipulate biological systems" is deceptively specific. It rules out most of the TechBio landscape - the apps, the dashboards, the analytics wrappers - and zeroes in on companies doing something to biology, not just watching it.

He has led investments for the firm in AI platforms applied to biology, manufacturing, and materials design; he has also invested in novel tools that measure and manipulate biological systems, as well as in novel compute, such as quantum computing.

- DCVC on James Hardiman's investment focus

Hardiman's optimism about technology is not unearned cheerleading. His X/Twitter presence is sparse and pointed - when he does post, it tends to be a dispatch from a company doing something real, not a meditation on hype cycles. The quote "the future is going to be awesome - all that's required is that we all work hard together to make it happen" reads less like a platitude and more like a personal operating principle.

He describes himself as "physicist at heart" - a framing that suggests the labs came before the partner meetings, and the instinct to understand how things actually work hasn't been replaced by the instinct to pattern-match on traction metrics.

🧲
What DCVC Does Differently

DCVC's GPs have deep scientific backgrounds, not just financial ones. They sit on boards, write technical analyses, and make investment decisions most generalist funds wouldn't recognize as opportunities. Hardiman is a defining example of that model.

📐
Investment Parameters

Stages: Seed, Series A, Series B.
Check size: $5M to $25M, sweet spot ~$15M.
Fund: $725M (latest), $2B+ total DCVC raised.
Engagement: Board director or observer, not passive.

🎓
Academic Roots

BS Engineering Physics, UC Berkeley.
MBA, University of Chicago Booth School of Business.
His Twitter bio lists both schools as institutions he actively supports.

Things You Didn't
Know to Ask

Three Things
Rarely Coexist

⚗️
Genuine Scientific Depth

Engineering physics isn't a minor in chemistry. It's thermodynamics, quantum mechanics, electromagnetism, and semiconductor physics - the kind of training that lets you spot when someone's hand-waving on the science versus when they're describing something real.

📊
Commercial Translation

Five years consulting at ZS Associates in healthcare and biotech means Hardiman understands how hard science needs to be packaged, sold, and deployed in industries that move slowly and at massive scale. He's not just a scientist who learned to invest - he's someone who built the bridge first.

🏗️
Long-Horizon Conviction

Joining DCVC in 2013, staying through the cycles, and being made GP in 2023 - that's ten years of compounding knowledge about what deep tech actually looks like when it works, versus when it looks like it's working. That decade is the product.

Share: 𝕏 Twitter in LinkedIn f Facebook